AlphAIAlphAI — Financial news for AI agents
tradingview.com$ESTA

Establishment Labs 3Q 2026: Revenue $71.99M, EPS ($0.35) — 10-Q Summary

Establishment Labs reported 3Q 2026 revenue of $71.99M, up 33.9% YoY, with net loss narrowing to ($10.71M). U.S. sales led growth, while gross margin declined to 69.1% due to restructuring and lower-margin sales.

Original reporting
tradingview.com
Published Nov 6, 2026, 10:01 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 6, 2026, 10:11 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
Establishment Labs 3Q 2026: Revenue $71.99M, EPS ($0.35) — 10-Q Summary — source image
Source · tradingview.com
Decision brief

The 30-second read

$ESTANeutralLow
01

Why it matters

The earnings release provides fresh data on revenue growth and loss improvement, offering limited trading edge.

02

Market read

Micro‑cap earnings release with modest upside potential; relevance mainly to traders tracking medical‑device stocks.

03

What to watch

Potential future cost reductions from restructuring and inventory normalization may improve profitability.

Relevance 6/10Novelty 7/10Timing: post-market release

Background

Establishment Labs Holdings Inc. filed its Q3 2026 10‑Q, reporting higher revenue and a narrowed loss.

Company-level read

Ticker impact

$ESTANeutralHigh confidence
Context

Q3 2026 revenue $71.99M (+33.9% YoY) and EPS -$0.35, net loss narrowed versus prior quarter.

Expected impact

modest upside as the market prices in the narrowed loss and revenue beat

Evidence & confidence

Revenue beat and loss improvement are positive, but lower gross margin and ongoing restructuring limit upside.

Market effects

Sector

Shows continued demand for minimally invasive medical devices, but margin compression may pressure peers.

Regional

U.S. sales drive growth; international sales modestly contribute.

Global

Limited to medical device niche; no broad market effect.

Counterpoint

What could challenge this read

Margin deterioration and restructuring costs could outweigh revenue growth, leading to a sell-off.

Key entities

  • company
    Establishment Labs Holdings Inc.

    Medical device manufacturer reporting Q3 2026 results.

Read at source← All news

Related articles

$ESTAMed

Mizuho reiterates Establishment Labs stock rating on strong sales

Mizuho reiterated an Outperform rating and $105 price target for Establishment Labs (ESTA) after its Q3 results. The company beat revenue estimates by $5M, with U.S. sales up 4% YoY and international sales up 10% YoY. ESTA raised 2026 revenue guidance to over $274M. Q3 revenue grew 34% YoY to $72M, but EPS loss of $0.35 missed estimates. BTIG lowered its price target to $93 but maintained a Buy rating.

investing.com
$ESTAMedAI 8/10

Establishment Labs Holdings Inc (ESTA) Q3 2026 Earnings Call Highlights: US Revenue Surges

Establishment Labs (ESTA) reported Q3 2026 earnings with US revenue up 119%. CFO Sandra Harris expects 50-100 basis points of gross margin expansion in 2027. CEO Peter Caldini anticipates FDA approval for Motiva implants by late 2026 or early 2027. The company raised its full-year minimally invasive revenue expectation to over $40M. International markets are stable, with 16% growth in direct markets. The company is investing in its commercial team ahead of potential reconstruction approval.

finance.yahoo.com
$ESTAMed

Establishment Labs Holdings Inc. Q3 2026 Earnings Call Summary

Establishment Labs reported Q3 2026 revenue growth of 33.9%, driven by U.S. market share gains and a 124% increase in minimally invasive revenue. The company achieved positive free cash flow and expects 25% revenue growth in 2027, supported by increased U.S. utilization and FDA approval for Motiva implants in reconstruction. Gross margin expansion of 50 to 100 basis points is projected for 2027, with growth driven by leadership optimization in international markets.

finance.yahoo.com
$ESTAMed

Establishment Labs stock price target lowered to $93 by BTIG on estimates

BTIG lowered its price target on Establishment Labs (ESTA) to $93 from $103, maintaining a Buy rating. The company reported Q3 revenue of $72.0M, up 34% YoY, and adjusted EBITDA of $6.4M, exceeding estimates. ESTA raised its 2026 revenue guidance to at least $274M. The stock gained 8.6% over the past week, trading at $69.74. BTIG adjusted its 2027 and 2028 estimates due to a more conservative timeline for U.S. reconstruction approval.

investing.com
$ESTAMed

What Establishment Labs (ESTA) Said on Its Q3 Earnings Call

Establishment Labs (ESTA) reported $75.8M in cash, targeting positive free cash flow for 2027. U.S. accounts grew to 2,100, with 30% market share. Minimally invasive revenue rose 124% YoY to $9M, raising full-year guidance to over $40M. International revenue increased 16% YoY, led by Europe. GAAP gross margin was 69.1%, with adjusted margin at 70.8%. The company prepares for potential FDA approval of Motiva implants for reconstruction.

finance.yahoo.com